An observational study in Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1) and Myotonic Dystrophy Type 2, sponsored by LMU Klinikum. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-24.
Sponsored by LMU Klinikum · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Glycogen Storage Disease Type II with a site in Germany — 9 open to participants now, 13 under way, 3 of them phase 3. Glycogen Storage Disease Type II · Germany.
Among the 34 studies in Glycogen Storage Disease Type II with a site in Germany, this one is the 7th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2021, is one of 12 observational ones, and was the 24th registered.
162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.
Browse Glycogen Storage Disease Type II studies →9 of the 34 studies in Glycogen Storage Disease Type II with a site in Germany are open now. Recruiting first, the newest first:
Denali Therapeutics Inc. · Sites in Germany, United States, Netherlands and 1 more country
Ages 18–75
Shionogi · Sites in Germany, United States, Belgium and 6 more countries
Ages 18+
Amicus Therapeutics · Sites in Germany, United States, Austria and 9 more countries
Amicus Therapeutics · Sites in Germany, United States, Italy and 3 more countries
Ages up to 17
LMU Klinikum · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 8 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2021.
This study's enrollment of 82 is above the median of 50 across 64 observational studies indexed under Glycogen Storage Disease Type II.
Median enrollment 24 across the 22 interventional studies, 89 across the 12 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 34 have an industry lead sponsor. The 10 most frequent:
LMU Klinikum is the lead sponsor of 53 studies on the registry; 20 are open to participants now.
LMU Klinikum has 5 studies filed under Glycogen Storage Disease Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Glycogen Storage Disease Type II with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03911505Phase 3Amicus TherapeuticsZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | 2027-03 |
| NCT04808505Phase 3Amicus TherapeuticsA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | 2027-07 |
| NCT07072676LMU KlinikumThe Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. | 2027-05-01 |
| NCT06150820Astellas Gene TherapiesA Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease | 2027-06-30 |
| NCT06605612LMU KlinikumDevelopment and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders | 2027-08-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 34 studies in Glycogen Storage Disease Type II with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD). The secondary objectives are to evaluate whether severity and distribution of muscle pain is associated with muscle function, and to assess whether muscle pain is associated with alterations of muscle elasticity and muscle stiffness. Results of patients with neuromuscular disorders will be compared to age- and gender-matched healthy volunteers. Approx. 70 patients with neuromuscular disorders and 20 healthy volunteers will be enrolled, including patients with the following neuromuscular disorders: histologically confirmed inclusion body myositis (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD), genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). The duration of patient recruitment will be around 12 months.
The explorative, cross-sectional low-interventional pilot study evaluates the prevalence, severity and quality of musculoskeletal nociceptive pain in participants with defined neuromuscular disorders (NMD). Adult participants with the following neuromuscular disorders will be included: histologically confirmed inclusion body myositis (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) and genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). 20 healthy participants will be enrolled as a control group. The Beck depression inventory fast screen (BDI-FS) will be used as a screening. If there is a possibility of major depression (with a BDI ≥4), patients will be excluded from the study. So only patients with BDI-FS score ≤3 at screening will be enrolled. Patients will be asked to complete the following validated disease-related and quality-of-life questionnaires: German Pain Inventory (module A and abbreviated module S and L and V), Brief Pain Inventory (BPI) and Fatigue Severity and Disability Scale (FSS). Demographic and disease related data will be obtained. A neuromuscular examination will be conducted. A clinical evaluation of muscle strength using the MRC-Scale (Medical Research Council-Scale) will be performed on both sides deltoid muscles, biceps brachii muscles, triceps brachii muscles, hip flexors, hip extensors, quadriceps femoris muscles, foot extensor and foot flexor muscles as well as axial muscles and neck flexors and extensors. The Quick Motor Function Test (QMFT) with 16 items will be performed to assess muscle and movement functions of the participants. To ensure a high level of objective measurement, muscle strength will also be assessed by using handheld dynamometry. The following muscle groups will be tested: arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion. A six-minute-walk test (6MWT) will be performed once. Additionally, first signs of muscle pain or muscle cramps will be recorded (including the quality and intensity of pain). The Borg scale to rate dyspnea will be administered before starting the 6MWT and after completing the 6MWT. For diagnosis of myofascial pain, a Pressure Pain Threshold test by using a pressure algometer is included for the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles until the patient feels any sensation of pain. Measurement of muscle stiffness, muscle tone, relaxation periods and viscoelasticity of selected muscles will be assessed by a myotonometer. Data collected in this study will be reported using summary tables, figures, and patient data listings. Differences between the patients and the healthy volunteers will be analyzed.
Approximately 70 patients with defined NMD (see inclusion criteria) will be enrolled. For a control group, 20 healthy volunteers will be enrolled. All patients must be ≥ 18 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has one of the following diagnoses:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient has one of the following neuromuscular diagnoses: 1. histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or 2. genetically confirmed late-onset Pompe disease (LOPD), or 3. genetically confirmed spinal muscular atrophy type 3 (SMA3), or 4. genetically confirmed myotonic dystrophy type 1, or 5. genetically confirmed myotonic dystrophy type 2, or 6. genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD).
Diagnostic Test: Beck depression inventory fast screen · Diagnostic Test: German Pain Inventory · Diagnostic Test: Brief Pain Inventory · Diagnostic Test: Fatigue Severity and Disability Scale (FSS) · Diagnostic Test: Quick Motor Function Test · Diagnostic Test: Handheld Dynamometry (HHD) · Diagnostic Test: Six-minute walk test (6MWT) · Diagnostic Test: Pressure pain threshold · Diagnostic Test: Myotonometer Assessment · Diagnostic Test: Vital signs · Diagnostic Test: Borg Scale
no known neuromuscular disorder
Diagnostic Test: Beck depression inventory fast screen · Diagnostic Test: German Pain Inventory · Diagnostic Test: Brief Pain Inventory · Diagnostic Test: Fatigue Severity and Disability Scale (FSS) · Diagnostic Test: Quick Motor Function Test · Diagnostic Test: Handheld Dynamometry (HHD) · Diagnostic Test: Six-minute walk test (6MWT) · Diagnostic Test: Pressure pain threshold · Diagnostic Test: Myotonometer Assessment · Diagnostic Test: Vital signs · Diagnostic Test: Borg Scale
Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
Also known as: BDI-FS
German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
Also known as: Deutscher Schmerzfragebogen (DSF)
Validated questionnaire for pain.
Also known as: BPI
Validated questionnaire for perceived fatigue
Also known as: FSS
An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
Also known as: QMFT
To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
Also known as: HHD
It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
Also known as: 6MWT
For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of "burning", "stinging", "drilling" or "aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
Also known as: PPT
Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
Also known as: Vital parameters (VP)
the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
Prevalence of musculoskeletal pain in defined neuromuscular diseases
The primary aim is to characterize the prevalence of musculoskeletal pain in adult patients with neuromuscular disorders (NMD).
Time frame: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by Medical research council (MRC) grading (0-5)
Assessed by Medical research council (MRC) grading (0-5)
Time frame: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by quick motor function test (QMFT)
Assessed by quick motor function test (QMFT)
Time frame: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by Pressure Pain Threshold (PPT)
Assessed by Pressure Pain Threshold (PPT)
Time frame: Only at baseline visit
Association between musculoskeletal pain and muscle function, assessed by a Myotonometer
Assessed by a Myotonometer (incl. relaxation time, stiffness, muscle tone, relaxation periods and viscoelasticity)
Time frame: Only at baseline visit
Assessment of Questionnaire: Beck depression inventory fast screen
Association between Depression and musculoskeletal pain
Time frame: Only at baseline visit
Assessment of Questionnaire: Brief Pain Inventory
Association between Depression and musculoskeletal pain
Time frame: Only at baseline visit
Assessment of Questionnaire: Fatigue Severity Scale (FSS)
Association between Depression and musculoskeletal pain
Time frame: Only at baseline visit
Characterization of musculoskeletal pain (quality and severity) assessed by the German Pain Questionnaire
Characterization of quality and severity of musculoskeletal pain
Time frame: Only at baseline visit
Characterization of musculoskeletal pain (quality and severity) assessed by the Brief Pain Inventory (BPI)
Characterization (quality and severity) of musculoskeletal pain
Time frame: Only at baseline visit
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Aug 2022, 16 months.
Of 29 observational studies under Glycogen Storage Disease Type II, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 33. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glycogen Storage Disease Type II →
LMU Klinikum